Atlassian R&D increased by 12.2% to $926.95M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 35.3%, from $685.32M to $926.95M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 30.1% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $233.25M | $272.14M | $318.57M | $334.16M | $367.01M | $399.01M | $473.68M | $522.34M | $474.86M | $481.74M | $536.78M | $576.49M | $589.10M | $603.10M | $680.21M | $685.32M | $700.68M | $755.99M | $826.49M | $926.95M |
| QoQ Change | — | +16.7% | +17.1% | +4.9% | +9.8% | +8.7% | +18.7% | +10.3% | -9.1% | +1.4% | +11.4% | +7.4% | +2.2% | +2.4% | +12.8% | +0.8% | +2.2% | +7.9% | +9.3% | +12.2% |
| YoY Change | — | — | — | — | +57.3% | +46.6% | +48.7% | +56.3% | +29.4% | +20.7% | +13.3% | +10.4% | +24.1% | +25.2% | +26.7% | +18.9% | +18.9% | +25.4% | +21.5% | +35.3% |